← Back to Search

Other

Pulmonary Arterial Hypertension Patients Receving Sotatercept for Pulmonary Hypertension (Sox-PH Trial)

Phase 2

Waitlist Available

Led By Sudarshan Rajagopal, MD, PhD

Research Sponsored by Bastiaan Driehuys

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, 3, 6 and 12 months

Awards & highlights

Sox-PH Trial Summary

"This trial aims to see if a special type of MRI/MRS scan using 129Xe can help track changes in the blood vessels in the lungs of people with PAH who are receiving sot

Who is the study for?

This trial is for patients with Pulmonary Arterial Hypertension (PAH), a type of high blood pressure affecting the lungs. Specific eligibility criteria are not provided, but typically participants must meet certain health standards and may be required to have a confirmed diagnosis of PAH.Check my eligibility

What is being tested?

The study is testing how well a special type of lung imaging called '129 Xenon Imaging' can track changes in the lungs caused by Sotatercept treatment in PAH patients. This involves using MRI/MRS technology to create detailed images.See study design

What are the potential side effects?

Potential side effects are not listed for this specific procedure, but generally, MRI/MRS scans are considered safe. There might be risks related to inhaling hyperpolarized xenon gas used during imaging; however, these should be minimal.

Sox-PH Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, 3, 6 and 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, 3, 6 and 12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 3, 6 and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in Xenon MRI Red Blood Cell (RBC) percentage

Change in cardiogenic oscillation amplitudes

Sox-PH Trial Design

1Treatment groups

Experimental Treatment

Group I: Pulmonary Arterial Hypertension Patients Receving SotaterceptExperimental Treatment1 Intervention

PAH patients receiving sotatercept as treatment for their PAH

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Merck Sharp & Dohme LLCIndustry Sponsor

3,892 Previous Clinical Trials

5,061,128 Total Patients Enrolled

Bastiaan DriehuysLead Sponsor

14 Previous Clinical Trials

1,067 Total Patients Enrolled

Sudarshan Rajagopal, MD, PhDPrincipal InvestigatorDuke University

4 Previous Clinical Trials

116 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this medical study actively seeking participants at the moment?

"As per clinicaltrials.gov, this particular trial is not in the process of recruiting participants. Initially listed on June 1st, 2024 and last modified on April 2nd, 2024. Despite this trial being inactive for recruitment, there are currently a substantial number of other trials (760) actively seeking patient enrollment."

Answered by AI

What is the level of risk associated with administering sotatercept to individuals diagnosed with pulmonary arterial hypertension?

"Given that this is a Phase 2 trial with available safety data but lacking efficacy evidence, our team at Power rates the safety of Sotatercept treatment for patients with Pulmonary Arterial Hypertension as a 2 on the scale from 1 to 3."

Answered by AI

Is it possible for me to participate in this research trial?

"Individuals aged between 18 and 75 years with a confirmed diagnosis of pulmonary arterial hypertension are eligible to participate in this trial, which aims to enroll approximately 14 individuals."

Answered by AI

Are individuals aged 70 and above being considered as participants in this study?

"Eligible candidates for participation in this research endeavor must range from 18 to 75 years old. Notably, there are a total of 51 investigations focusing on individuals below the age of 18 and another 671 studies targeting patients over the age of 65."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

129 Xenon Imaging in Patients Treated With Sotatercept

Bastiaan Driehuys 2024. "129 Xenon Imaging in Patients Treated With Sotatercept". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06351345.

All > Pulmonary Arterial Hypertension > Pulmonary Hypertension